Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
Abroad (travel likely)Recruiting
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hospital Of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study leads
Shampa Chatterjee, PhD
Principal Investigator
University of Pennsylvania
Christian Bermudez, MD
Principal Investigator
University of Pennsylvania
Asad Usman, MD
Study Director
University of Pennsylvania